Initial results of a phase 2 pilot study of radium-223 and radiotherapy in untreated hormone-naive men with oligometastatic prostate cancer to bone.

被引：0
|
作者：
Tward, Jonathan David
Johnson, Skyler B.
Kokeny, Kristine E.
Lloyd, Shane
Cannon, Donald Maurice
Dechet, Christopher B.
ONeil, Brock
Stephenson, Robert
Boucher, Kenneth M.
Gupta, Sumati
Swami, Umang
Maughan, Benjamin L.
Agarwal, Neeraj
机构：
[1] Univ Utah, Hunstman Canc Inst, Salt Lake City, UT USA
[2] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA
[3] Huntsman Canc Hosp, Salt Lake City, UT USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
156
引用
收藏
页数：1
相关论文
共 50 条
  • [31] A phase II study of enzalutamide (Enz) with dutasteride (Dut) or finasteride (Fin) in men ≥ 65 years with hormone-naive systemic prostate cancer (HNSPCa)
    Kilari, D.
    Guancial, E.
    Sahasrabudhe, D.
    Bylow, K.
    Sievert, L.
    Schaffer, K.
    Riese, M.
    Burfeind, J.
    Musto, K.
    Feng, C.
    Messing, E.
    Mohile, S.
    Fung, C.
    ANNALS OF ONCOLOGY, 2017, 28
  • [32] Radium-223 in combination with docetaxel in patients with castration-resistant prostate cancer and bone metastases: a phase 1 dose escalation/randomised phase 2a trial
    Morris, Michael J.
    Loriot, Yohann
    Sweeney, Christopher J.
    Fizazi, Karim
    Ryan, Charles J.
    Shevrin, Daniel H.
    Antonarakis, Emmanuel S.
    Pandit-Taskar, Neeta
    Deandreis, Desiree
    Jacene, Heather A.
    Vesselle, Hubert
    Petrenciuc, Oana
    Lu, Cindy
    Carrasquillo, Jorge A.
    Higano, Celestia S.
    EUROPEAN JOURNAL OF CANCER, 2019, 114 : 107 - 116
  • [33] A phase II study of enzalutamide (Enz) with dutasteride (Dut) or finasteride (Fin) in men ≥ 65 years with hormone-naive systemic prostate cancer (HNSPCa).
    Kilari, Deepak
    Cuancial, Elizabeth A.
    Sahasrabudhe, Deepak M.
    Bylow, Kathryn A.
    Burfeind, John D.
    Musto, Kaylinn
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [34] Safety of radium-223 dichloride (Ra-223) with docetaxel (D) in patients with bone metastases from castration-resistant prostate cancer (CRPC): A phase I Prostate Cancer Clinical Trials Consortium Study
    Morris, Michael J.
    Hammers, Hans J.
    Sweeney, Christopher
    Antonarakis, Emmanuel S.
    Cho, Steve Y.
    Pandit-Taskar, Neeta
    Jacene, Heather
    Bloma, Marianne
    Aksnes, Anne-Kirsti
    O'Bryan-Tear, C. Gillies
    Carrasquillo, Jorge A.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [35] Pain analyses from the phase 3 randomized ALSYMPCA study with radium-223 dichloride (Ra-223) in castration-resistant prostate cancer (CRPC) patients with bone metastases
    Schrader, A. J.
    Nilsson, S.
    Sartor, O.
    Bruland, O.
    Fang, F.
    Aksnes, A-K
    Parker, C.
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 59 - 59
  • [36] Pain analysis from the phase III randomized ALSYMPCA study with radium-223 dichloride (Ra-223) in patients with castration-resistant prostate cancer (CRPC) with bone metastases
    Nilsson, Sten
    Sartor, A. Oliver
    Bruland, Oyvind S.
    Fang, Fang
    Aksnes, Anne-Kirsti
    Parker, Chris
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [37] Pain analyses from the phase 3 randomized ALSYMPCA study with radium-223 dichloride (Ra-223) in castration-resistant prostate cancer (CRPC) patients with bone metastases
    Schrader, A. J.
    Nilsson, S.
    Sartor, O.
    Bruland, O.
    Fang, F.
    Aksnes, A. K.
    Parker, C.
    ONKOLOGIE, 2013, 36 : 17 - 18
  • [38] Quantification of normal bone and osseous metastases in castration-resistant prostate cancer using SPECT/CT with xSPECT Quant: prospective imaging sub-study of a phase 2 clinical trial investigating the combination of pembrolizumab plus radium-223 compared to radium-223 alone
    Robertson, Matthew S.
    Wang, Yating
    Cheng, SuChun
    Park, Hyesun
    Glomski, Shahar
    Harshman, Lauren C.
    Pace, Amanda
    Kilar, Jacqueline
    Flynn, Meredith
    Gilbert, Lauren
    Choudhury, Atish D.
    Jacene, Heather
    RADIOLOGIA MEDICA, 2025, 130 (01): : 132 - 142
  • [39] Role of serum biomarkers of bone metabolism in metastatic castration-resistance prostate cancer (mCRPC) patients (pts) treated with radium-223 (Ra223): PRORADIUM study final results
    Romero Laorden, N.
    Lorente, D.
    Lozano Mejorada, R.
    Sanchez-Soler, N.
    De Velasco, G.
    Puente, J.
    Borrega, P.
    Gonzalez-Billalabeitia, E.
    Castillo-Morales, V.
    Hernandez, A.
    Fernandez-Freire, A.
    Lopez Campos, F.
    Villatoro, R.
    Fernandez Calvo, O.
    Anido, U.
    Lainez, N.
    Luque, R.
    Ros Martinez, S.
    Castro, E.
    Olmos, D.
    ANNALS OF ONCOLOGY, 2021, 32 : S648 - S648
  • [40] Serum biomarkers of bone metabolism in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with radium-223 (Ra223): Results from a prospective multicentre study
    Romero Laorden, N.
    Lozano Mejorada, R.
    Hernandez Jorge, A.
    Lainez, N.
    Almagro Casado, E.
    Fernandez Calvo, O.
    Hernando, S.
    Fernandez Freire, A.
    Gonzalez Billalabeitia, E.
    Chirivella, I.
    Garcia Dominguez, R.
    Anido Herranz, U.
    Vazquez Mazon, F. J.
    Ros, S.
    Montesa, A.
    De Velasco Oria de Rueda, G. A.
    Morales Barrera, R.
    Lorente, D.
    Castro, E.
    Olmos Hidalgo, D.
    ANNALS OF ONCOLOGY, 2019, 30 : 344 - 344
12345